SFI
ZNTL icon

Susquehanna Fundamental Investments’s Zentalis Pharmaceuticals ZNTL Stock Holding History

Susquehanna Fundamental Investments’s Portfolio ZNTL Stock Details ZNTL Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2025
Q2 		– Sell
-159,836
Closed -$254K – 1044
2025
Q1 		$254K Buy
+159,836
New +$345K ﹤0.01% 969

Other funds holding ZNTL

MCMC
Matrix Capital Management Company Portsmouth, New Hampshire $46.3M AUM 114.38% 1-Year Est. Return
Millennium Management
Millennium Management New York $240B AUM 35.51% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
Acadian Asset Management
Acadian Asset Management Boston, Massachusetts $70.5B AUM 36% 1-Year Est. Return
OM
Opaleye Management Boston, Massachusetts $759M AUM 124.8% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
AC
Almitas Capital Santa Monica, California $443M AUM 42.36% 1-Year Est. Return
TCM
Tang Capital Management San Diego, California $1.97B AUM 125.1% 1-Year Est. Return
Renaissance Technologies
Renaissance Technologies New York $63.9B AUM 45.56% 1-Year Est. Return
TCM
Tybourne Capital Management Hong Kong $30.9M AUM 20.1% 1-Year Est. Return

Susquehanna Fundamental Investments's ZNTL Position: Q2 2025 in Review

Susquehanna Fundamental Investments sold out of Zentalis Pharmaceuticals (ZNTL) in Q2 2025, closing a stake of 159,836 shares — an estimated $254K sold.

Susquehanna Fundamental Investments first reported a position in ZNTL in Q1 2025 and held it in 1 quarter. The position peaked at $254K in Q1 2025. 117 funds tracked by Wall St. Rank hold ZNTL as of Q2 2025.

  • Susquehanna Fundamental Investments reported no remaining Zentalis Pharmaceuticals position as of Q2 2025 after selling out during the quarter.
  • Susquehanna Fundamental Investments sold 159,836 Zentalis Pharmaceuticals shares in Q2 2025, an estimated $254K.
  • Susquehanna Fundamental Investments first reported a position in Zentalis Pharmaceuticals in Q1 2025 and held it in 1 quarter.
  • Susquehanna Fundamental Investments's Zentalis Pharmaceuticals position peaked at $254K in Q1 2025.
  • 117 funds tracked by Wall St. Rank held Zentalis Pharmaceuticals as of Q2 2025.

Based on Susquehanna Fundamental Investments's 13F filing for Q2 2025, filed 14 Aug 2025.